Advertisement

Metabolic syndrome, obesity, and the risk of cancer development

  • Author Footnotes
    1 Equally contributed.
    Rafael Bitzur
    Footnotes
    1 Equally contributed.
    Affiliations
    The Bert W. Strassburger Lipid Center, Sheba Medical Center, 5265601 Tel Hashomer, Israel

    Sackler Faculty of Medicine, Tel-Aviv University, Ramat-Aviv, Israel
    Search for articles by this author
  • Author Footnotes
    1 Equally contributed.
    Ronen Brenner
    Footnotes
    1 Equally contributed.
    Affiliations
    Sackler Faculty of Medicine, Tel-Aviv University, Ramat-Aviv, Israel

    Institute of Oncology, Wolfson Medical Center, Holon, Israel
    Search for articles by this author
  • Elad Maor
    Affiliations
    Sackler Faculty of Medicine, Tel-Aviv University, Ramat-Aviv, Israel

    Leviev Heart Institute, The Chaim Sheba Medical Center, Tel Hashomer, Israel

    The Dr. Pinchas Borenstein Talpiot Medical Leadership Program 2013, Sheba Medical Center, Tel Hashomer, Israel
    Search for articles by this author
  • Maayan Antebi
    Affiliations
    Department of Internal Medicine D, The Chaim Sheba Medical Center, Tel Hashomer, Israel
    Search for articles by this author
  • Tomer Ziv-Baran
    Affiliations
    Department of Epidemiology and Preventive Medicine, School of Public Health, Sackler Faculty of Medicine, Tel-Aviv University, Ramat-Aviv, Israel
    Search for articles by this author
  • Shlomo Segev
    Affiliations
    Institute for Medical Screening, Sheba Medical Center, Israel
    Search for articles by this author
  • Yechezkel Sidi
    Affiliations
    Sackler Faculty of Medicine, Tel-Aviv University, Ramat-Aviv, Israel

    Department of Internal Medicine C, The Chaim Sheba Medical Center, Tel Hashomer, Israel
    Search for articles by this author
  • Shaye Kivity
    Correspondence
    Corresponding author at: Department of Medicine A, Sheba Medical Center, Tel Hashomer 52621, Israel.
    Affiliations
    Sackler Faculty of Medicine, Tel-Aviv University, Ramat-Aviv, Israel

    The Dr. Pinchas Borenstein Talpiot Medical Leadership Program 2013, Sheba Medical Center, Tel Hashomer, Israel

    Department of Internal Medicine A, The Chaim Sheba Medical Center, Tel Hashomer, Israel
    Search for articles by this author
  • Author Footnotes
    1 Equally contributed.
Published:August 18, 2016DOI:https://doi.org/10.1016/j.ejim.2016.08.019

      Highlights

      • In a cohort of healthy Israeli subjects, the cancer incidence during ~ 8.5 years follow-up was 5.7%, the prevalence of metabolic syndrome was 15.7%, and obesity (BMI > 30) 14.2%.
      • Neither metabolic syndrome nor obesity did not correlate with an increase in all type cancer incidences.
      • Metabolic syndrome was associated with higher incidence of breast cancer.

      Abstract

      Background

      Metabolic syndrome and its components are severe global health issues that are increasing in frequency as the prevalence of obesity increases. Various studies have established a correlation between metabolic syndrome and diseases including, diabetes mellitus, non-alcoholic fatty liver disease, cirrhosis, and cardiovascular disease. In recent years, correlations have also been detected between obesity and metabolic syndrome and the prevalence of certain types of cancer. The current study examines whether obesity and metabolic syndrome components are risk factors for cancer among the adult population in Israel.

      Methods

      A cohort study analysis was performed of 24,987 initially healthy men and women who underwent yearly medical assessments at the Institute for Medical Screening in the Sheba Medical Center. Data from the Institute for Medical Screening database was correlated with that from the Israel Cancer Center in the Ministry of Health updated to December 2013. The correlation between metabolic syndrome, obesity, and the overall risk of cancer as well as the risks of specific types of cancer were examined.

      Results

      Of 20,444 subjects for whom complete data were available, 1535 were diagnosed with cancer during the mean follow-up time of 104.3 months. In a multi-variant analysis, no significant correlation was found between metabolic syndrome or obesity and the incidence of cancer. When the data were stratified by gender and cancer type, however, a significant association between metabolic syndrome and breast cancer in women was observed (P = 0.03, HR = 1.67, 95% CI = 1.05–2.67).

      Conclusion

      Metabolic syndrome correlates with higher than expected breast cancer incidence in women.

      Abbreviations:

      BMI (body mass index), CRP (C-reactive protein), PSA (prostate-specific antigen), HDL (High-density lipoprotein)

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to European Journal of Internal Medicine
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Isomaa B.
        • Almgren P.
        • Tuomi T.
        • et al.
        Cardiovascular morbidity and mortality associated with the metabolic syndrome.
        Diabetes Care. Apr 2001; 24: 683-689
        • Aguilar M.
        • Bhuket T.
        • Torres S.
        • Liu B.
        • Wong R.J.
        Prevalence of the metabolic syndrome in the United States, 2003–2012.
        JAMA. May 19 2015; 313: 1973-1974
        • Ogden C.L.
        • Carroll M.D.
        • Kit B.K.
        • Flegal K.M.
        Prevalence of childhood and adult obesity in the United States, 2011–2012.
        JAMA. Feb 26 2014; 311: 806-814
      1. Health ICfDCI.
        • Cohen E.
        • Krause I.
        • Fraser A.
        • Goldberg E.
        • Garty M.
        Hyperuricemia and metabolic syndrome: lessons from a large cohort from Israel.
        Isr Med Assoc J. Nov 2012; 14: 676-680
        • Stocks T.
        • Lukanova A.
        • Bjorge T.
        • et al.
        Metabolic factors and the risk of colorectal cancer in 580,000 men and women in the metabolic syndrome and cancer project (Me-Can).
        Cancer. Jun 1 2011; 117: 2398-2407
        • Bjorge T.
        • Lukanova A.
        • Jonsson H.
        • et al.
        Metabolic syndrome and breast cancer in the me-can (metabolic syndrome and cancer) project.
        Cancer Epidemiol Biomarkers Prev. Jul 2010; 19: 1737-1745
        • Welzel T.M.
        • Graubard B.I.
        • Zeuzem S.
        • El-Serag H.B.
        • Davila J.A.
        • McGlynn K.A.
        Metabolic syndrome increases the risk of primary liver cancer in the United States: a study in the SEER-Medicare database.
        Hepatology. Aug 2011; 54: 463-471
        • Shaye K.
        • Amir T.
        • Shlomo S.
        • Yechezkel S.
        Fasting glucose levels within the high normal range predict cardiovascular outcome.
        Am Heart J. Jul 2012; 164: 111-116
        • Levin B.
        • Lieberman D.A.
        • McFarland B.
        • et al.
        Screening and surveillance for the early detection of colorectal cancer and adenomatous polyps, 2008: a joint guideline from the American Cancer Society, the US Multi-Society Task Force on Colorectal Cancer, and the American College of Radiology.
        CA Cancer J Clin. May-Jun 2008; 58: 130-160
      2. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Dec 17 2002. 1524-4539 (Electronic) 0009-7322 (Linking).

        • ministry Ih
        Cancer incidence trends.
        2016
        • Schemper M.
        • Smith T.L.
        A note on quantifying follow-up in studies of failure time.
        Control Clin Trials. Aug 1996; 17: 343-346
        • Bhaskaran K.
        • Douglas I.
        • Forbes H.
        • dos-Santos-Silva I.
        • Leon D.A.
        • Smeeth L.
        Body-mass index and risk of 22 specific cancers: a population-based cohort study of 5.24 million UK adults.
        Lancet. Aug 30 2014; 384: 755-765
        • Liu X.
        • Hemminki K.
        • Forsti A.
        • Sundquist K.
        • Sundquist J.
        • Ji J.
        Cancer risk in patients with type 2 diabetes mellitus and their relatives.
        Int J Cancer. Aug 15 2015; 137: 903-910
        • Muti P.
        • Quattrin T.
        • Grant B.J.
        • et al.
        Fasting glucose is a risk factor for breast cancer: a prospective study.
        Cancer Epidemiol Biomarkers Prev. Nov 2002; 11: 1361-1368
        • Liu X.
        • Ji J.
        • Sundquist K.
        • Sundquist J.
        • Hemminki K.
        The impact of type 2 diabetes mellitus on cancer-specific survival: a follow-up study in Sweden.
        Cancer. Mar 1 2012; 118: 1353-1361
        • La Torre G.
        • Sferrazza A.
        • Gualano M.R.
        • et al.
        Investigating the synergistic interaction of diabetes, tobacco smoking, alcohol consumption, and hypercholesterolemia on the risk of pancreatic cancer: a case–control study in Italy.
        Biomed Res Int. 2014; 2014: 481019
        • Mittal A.
        • Sathian B.
        • Chandrasekharan N.
        • Lekhi A.
        • Yadav S.K.
        Role of hypercholesterolemia in prostate cancer—case control study from Manipal Teaching Hospital Pokhara, Nepal.
        Asian Pac J Cancer Prev. 2011; 12: 1905-1907
        • Magura L.
        • Blanchard R.
        • Hope B.
        • Beal J.R.
        • Schwartz G.G.
        • Sahmoun A.E.
        Hypercholesterolemia and prostate cancer: a hospital-based case–control study.
        Cancer Causes Control. Dec 2008; 19: 1259-1266
        • Hayashi N.
        • Matsushima M.
        • Yamamoto T.
        • Sasaki H.
        • Takahashi H.
        • Egawa S.
        The impact of hypertriglyceridemia on prostate cancer development in patients aged ≥60 years.
        BJU Int. Feb 2012; 109: 515-519
        • Salgado-Montilla J.
        • Soto Salgado M.
        • Surillo Trautmann B.
        • Sanchez-Ortiz R.
        • Irizarry-Ramirez M.
        Association of serum lipid levels and prostate cancer severity among Hispanic Puerto Rican men.
        Lipids Health Dis. 2015; 14: 111
        • Harding J.L.
        • Sooriyakumaran M.
        • Anstey K.J.
        • et al.
        Hypertension, antihypertensive treatment and cancer incidence and mortality: a pooled collaborative analysis of 12 Australian and New Zealand cohorts.
        J Hypertens. Jan 2016; 34: 149-155
        • Furberg A.S.
        • Thune I.
        Metabolic abnormalities (hypertension, hyperglycemia and overweight), lifestyle (high energy intake and physical inactivity) and endometrial cancer risk in a Norwegian cohort.
        Int J Cancer. May 10 2003; 104: 669-676
        • Lindgren A.M.
        • Nissinen A.M.
        • Tuomilehto J.O.
        • Pukkala E.
        Cancer pattern among hypertensive patients in North Karelia, Finland.
        J Hum Hypertens. May 2005; 19: 373-379
        • Peeters P.H.
        • van Noord P.A.
        • Hoes A.W.
        • Fracheboud J.
        • Gimbrere C.H.
        • Grobbee D.E.
        Hypertension and breast cancer risk in a 19-year follow-up study (the DOM cohort). Diagnostic investigation into mammarian cancer.
        J Hypertens. Mar 2000; 18: 249-254
      3. Israel National Health Interview Survey 2007–2010 SF.
        • Locker G.Y.
        • Lynch H.T.
        Genetic factors and colorectal cancer in Ashkenazi Jews.
        Fam Cancer. 2004; 3: 215-221
        • Rubinstein W.S.
        Hereditary breast cancer in Jews.
        Fam Cancer. 2004; 3: 249-257
        • Struewing J.P.
        BRCA1 in special populations.
        Breast Dis. Apr 1998; 10: 71-75
      4. Statistics. ICBo.
        • Hursting S.D.
        • Hursting M.J.
        Growth signals, inflammation, and vascular perturbations: mechanistic links between obesity, metabolic syndrome, and cancer.
        Arterioscler Thromb Vasc Biol. Aug 2012; 32: 1766-1770
        • Hursting S.D.
        • Dunlap S.M.
        Obesity, metabolic dysregulation, and cancer: a growing concern and an inflammatory (and microenvironmental) issue.
        Ann N Y Acad Sci. Oct 2012; 1271: 82-87
        • Gallagher E.J.
        • LeRoith D.
        Insulin, insulin resistance, obesity, and cancer.
        Curr Diab Rep. Apr 2010; 10: 93-100
        • Braun S.
        • Bitton-Worms K.
        • LeRoith D.
        The link between the metabolic syndrome and cancer.
        Int J Biol Sci. 2011; 7: 1003-1015
        • Capasso I.
        • Esposito E.
        • Pentimalli F.
        • et al.
        Metabolic syndrome affects breast cancer risk in postmenopausal women: National Cancer Institute of Naples experience.
        Cancer Biol Ther. Dec 15 2010; 10: 1240-1243
        • Kendall A.
        • Folkerd E.J.
        • Dowsett M.
        Influences on circulating oestrogens in postmenopausal women: relationship with breast cancer.
        J Steroid Biochem Mol Biol. Feb 2007; 103: 99-109
        • Loucks E.B.
        • Magnusson K.T.
        • Cook S.
        • Rehkopf D.H.
        • Ford E.S.
        • Berkman L.F.
        Socioeconomic position and the metabolic syndrome in early, middle, and late life: evidence from NHANES 1999–2002.
        Ann Epidemiol. Oct 2007; 17: 782-790
        • Reynolds T.
        Report examines association between cancer and socioeconomic status.
        J Natl Cancer Inst. Oct 1 2003; 95: 1431-1433